The dual actions of cholinesterase inhibition and anti-amyloidogenesis indicated a potential use of 43 as symptomatic and disease-modifying agent for the treatment of AD, which deserved further studies in cholinergic impairment animal models. The gene discussed is BCHE; the disease is Alzheimer disease.